Status and progress of bronchial artery interventional therapy for advanced non-small cell lung cancer
10.13929/j.issn.1672-8475.2020.06.014
- VernacularTitle: 晚期非小细胞肺癌支气管动脉介入治疗研究现状
- Author:
Yuyi CHEN
1
Author Information
1. Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small-cell lung;
Chemoembolization, therapeutic
- From:
Chinese Journal of Interventional Imaging and Therapy
2020;17(6):374-377
- CountryChina
- Language:Chinese
-
Abstract:
Nowadays, the curative effect of traditional systemic chemotherapy has been in a dilemma for patients with advanced unresectable non-small cell lung cancer (NSCLC) who are negative for genetic mutations or programmed cell death 1 ligand 1 (PD-L1) expressions. Bronchial artery interventional therapy, represented by bronchial artery infusion (BAI) and bronchial artery chemoembolization (BACE), is a mature local treatment for advanced NSCLC which has prominent advantages in several aspects such as improving the concentration of chemotherapeutic drugs, blocking feeding arteries of tumor and reducing systemic adverse reactions. The mechanism, the characteristics of benefiting crowd as well as the current status of bronchial artery interventional treatment were reviewed in this article.
